Analyzing single-cell sequencing in pancreatic cancer patients
Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients
This study is trying to see how different treatments, like chemotherapy before surgery, affect the cells in the tumors of people with borderline resectable pancreatic cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Fujian Medical University Union Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Fuzhou, Fujian) |
| Trial ID | NCT06310902 on ClinicalTrials.gov |
What this trial studies
This observational study focuses on patients with resectable and borderline resectable pancreatic cancer, aiming to explore the tumor microenvironment using single-cell sequencing technology. It compares patients who undergo preoperative neoadjuvant chemotherapy with those who only have surgical intervention. By analyzing the cellular composition and interactions within the tumor microenvironment, the study seeks to address the limitations and variability in treatment strategies and outcomes for borderline resectable pancreatic cancer. The findings could provide insights into the efficacy of neoadjuvant chemotherapy and improve treatment approaches.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 75 with resectable or borderline resectable pancreatic cancer who have not received prior anti-tumor treatments.
Not a fit: Patients with a history of other malignant tumors, active autoimmune diseases, or those who have received live vaccines recently may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of pancreatic cancer treatment and lead to more effective therapeutic strategies.
How similar studies have performed: While the use of single-cell sequencing in cancer research is gaining traction, this specific approach in borderline resectable pancreatic cancer is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years ≤ age ≤ 75 years. * Resectable/borderline resectable pancreatic cancer patients diagnosed based on pathological and preoperative imaging evaluation. * No prior history of any form of anti-tumor treatment. * At least one measurable lesion. * Eastern Cooperative Oncology Group (ECOG): 0-1. * Not participated in any other clinical studies before or during treatment. * Willingness to participate voluntarily in this study, signing an informed consent form. Exclusion Criteria: * History of any other malignant tumor, except for completely resected basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, within the past 5 years. * Vaccination with live vaccines within 4 weeks prior to enrollment or during the study period. * Active autoimmune diseases or a history of autoimmune diseases within the past 4 weeks before enrollment. * Allogeneic bone marrow or organ transplantation. * Active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors in the gastrointestinal tract, or other conditions determined by the investigator that may cause gastrointestinal bleeding or perforation. * Evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding \>30 mL within 3 months, hematemesis, melena, or hematochezia), hemoptysis (\>5 mL of fresh blood within 4 weeks), or occurrence of thromboembolic events within 12 months (including stroke events and/or transient ischemic attacks).
Where this trial is running
Fuzhou, Fujian
- Fujian Medical University Union Hospital — Fuzhou, Fujian, China (Recruiting)
Study contacts
- Study coordinator: Yu Pan, M.D.
- Email: yupan199002@163.com
- Phone: +86 18900316399
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.